Abstract:Research and development of multi-target inhibitors has attracted increasing attention as anticancer therapeutics. B-RafV600E synergistically works with vascular endothelial growth factor receptor 2 (KDR) to promote the occurrence and progression of cancers, and the development of dual-target drugs simultaneously against these two kinds of kinase may offer a better treatment advantage. In this paper, docking and three-dimensional quantitative structure activity relationship (3D-QSAR) studies were performed on a series of dual B-Raf/KDR inhibitors with a novel hinge-binding group, [5,6]-fused bicyclic scaffold. Docking studies revealed optimal binding conformations of these compounds interacting with both B-Raf and KDR. Based on these conformations, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) 3D-QSAR models were constructed, and the best CoMFA (q²=0.542, r²=0.989 for B-Raf; q²=0.768, r²=0.991 for KDR) and CoMSIA models (q²=0.519, r²=0.992 for B-Raf; q²=0.849, r²=0.993 for KDR) were generated. Further external validations confirmed their predictability, yielding satisfactory correlation coefficients (r²pred=0.764 (CoMFA), r²pred=0.841 (CoMSIA) for B-Raf, r²pred=0.912 (CoMFA), r²pred=0.846 (CoMSIA) for KDR, respectively). Through graphical analysis and comparison on docking results and 3D-QSAR contour maps, key amino acids that affect the ligand-receptor interactions were identified and structural features influencing the activities were discussed. New potent derivatives were designed, and subjected to preliminary pharmacological evaluation. The study may offer useful references for the modification and development of novel dual B-Raf/KDR inhibitors.

Recent Advances in the Research and Development of B-Raf Inhibitors

Discovery of a Selective Inhibitor of Oncogenic B-Raf Kinase with Potent Antimelanoma Activity.

Design, Synthesis, and Biological Evaluation of New B-RafV600E Kinase Inhibitors

Advances in the Research of Raf Kinase Inhibitors and Drug Resistance Mechanisms

Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization

Identification and Biological Evaluation of Novel Type II B-Raf V600E Inhibitors.

Identification of Novel B-RafV600E Inhibitors Employing FBDD Strategy

Accurate Activity Predictions of B-Raf Type Ii Inhibitors Via Molecular Docking and Qsar Methods

In Silico Design of New B-Raf Kinase Type-II Inhibitors Through Combined Molecular Modeling Studies

Design and synthesis of N-(4-aminopyridin-2-yl)amides as B-Raf(V600E) inhibitors.

A patent review of RAF kinase inhibitors (2010-2018).

Small-Molecule Inhibitors of Raf for Treatment of Malignant Diseases

Molecular Docking and 3D-Qsar Studies on A Series of Fused Heterocyclic Amides As B-Raf Inhibitors

Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold As Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies

Design of potent B-Raf V600E inhibitors by multiple copy simulation search strategy.

A Patent Review of RAF Kinase Inhibitors (2010–2018)

A Patent Review of BRAF Inhibitors: 2013-2018

Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives As Potent Dual B-RafV600E/KDR Inhibitors Using Docking and 3D-QSAR Approaches.

Challenges and Opportunities in the Crusade of BRAF Inhibitors: From 2002 to 2022

Non-oxime inhibitors of B-Raf(V600E) kinase

Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy